Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK0826, ertapenem sodium, MK0826,Duration of Treatment: 8 Weeks
MK0826, ertapenem · 8 trials · 13 indications
| Name | Type | Description |
|---|---|---|
| MK0826, ertapenem sodium / Duration of Treatment: 14 Days | DRUG | - |
| MK0826, ertapenem sodium | DRUG | - |
| Comparator: cefotetan | DRUG | - |
| Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks | DRUG | - |
| MK0826, /Duration of Treatment : 8 Weeks | DRUG | - |
| Comparator: metronidazole / Duration of Treatment: 8 Weeks | DRUG | - |
| Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks | DRUG | - |
| MK0826, ertapenem sodium / Duration of Treatment - 24 weeks | DRUG | - |
| Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks | DRUG | - |
| Comparator: Ticarcillin/Clavulanate | DRUG | - |
| MK0826, ertapenem sodium /Duration of Treatment: 14 Days | DRUG | - |
| Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days | DRUG | - |
Inclusion Criteria: * Male or female patients, 20 years of age or older * Patients did not receive any systemic antibiotic before enrollment, or patients with failed clinical response (no improvement on symptoms or laboratory data) through previous antibiotic treatment * Patients who required thera...
MK0826, ertapenem is an anti-infective agent studied for treating complicated intra-abdominal infections, colorectal surgery infections, foot infections in diabetic patients, and other bacterial infections. It has been evaluated in Phase 3 trials for these indications, including intra-abdominal infections and sepsis.
MK0826, ertapenem is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. Merck is the sponsor of the clinical trials evaluating this anti-infective agent for various infection types.
MK0826, ertapenem is in Phase 3 clinical development. It has completed at least one Phase 3 trial, and additional Phase 2 and Phase 3 trials have also been completed. It is an investigational agent and has not been approved by the FDA for the studied indications.
MK0826, ertapenem has been studied in completed trials including NCT00481702, a Phase 3 trial in intra-abdominal infections; NCT00451386, a Phase 2 trial in pediatric patients with urinary tract infections, skin infections, or community-acquired pneumonia; NCT00398099, a Phase 3 trial in various infections; and NCT00397956, a Phase 3 trial in complicated infections including sepsis.
Yes, MK0826, ertapenem is also known as ertapenem sodium. The names MK0826 and ertapenem refer to the same anti-infective agent developed by Merck. Variations such as MK0826, ertapenem sodium /Duration of Treatment: 14 Days and MK0826, ertapenem/Duration of Treatment: 14 Days are alternative designations for the same compound.